Astrana Health, Inc.

NASDAQ:ASTH

Medical - Care Facilities

Healthcare
$29.65 +2.70%

+$1.03 today

Market cap
$1.47B
Beta
0.94
P/E (TTM)
63.3
EPS (TTM)
$0.62
52W Low $18.08High $40.13

Volume 0.52M

Average 0.51M

ASTH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Astrana Health, Inc.NASDAQ: ASTH

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $9.9M rose 26.7% year over year, ahead of the +11.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.1% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.

Context

  • Stock-based compensation amounted to 1.2% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of +11.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.9M-13.1% QoQ
Last fiscal yearDec 2025
$38.6M+11.8% YoY
LTMMar 2026
$40.69M+11.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.7%——
1 year+11.8%——
3-year CAGR+33.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
38.6M USD
Year-over-year change
+11.8%
4-year CAGR
+54.7%

Stock-Based Compensation vs competitors

How ASTH compares with its peers on the latest reported figures

  • ASTH's LTM Mar 2026 stock-based compensation of $40.69M is the 2nd largest of the 4 companies compared; the peer median is $38.65M.
  • Its year-over-year change of +11.2% is the 2nd highest of 4, against a peer median of -23.4%.
  • Stock-based compensation amounts to 1.2% of revenue for ASTH, versus a peer median of 0.7%.
ASTH Competitors Peer median
Stock-Based Compensation for ASTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUTXNutex Health, Inc.LTM Mar 2026$85.45M +62.2%+751.4%9.7%
ASTHAstrana Health, Inc.LTM Mar 2026$40.69M +11.2%+33.8%1.2%
AGLAgilon Health, Inc.LTM Mar 2026$38.65M -23.4%+20.1%0.7%
PRVAPrivia Health Group, Inc.LTM Jun 2026$0 -100.0%—0.0%
Peer median (excluding ASTH) $38.65M-23.4%+385.7%0.7%

Competitors are the stored peer set for ASTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income46.06M45.74M57.85M49.93M24.08M
Depreciation & Amortization17.52M17.54M17.75M27.93M45.75M
Deferred Income Tax7.67M(14.28M)(12.44M)(4.25M)(4.29M)
Stock-Based Compensation6.75M16.1M22.04M34.54M38.6M
Change in Working Capital(33.64M)(1.96M)(23.39M)(63.61M)(3.1M)
Accounts Receivables(21.63M)(33.97M)(20.57M)(11.1M)(7.16M)
Inventory(2.11M)27.61M12.16M00
Accounts Payables4.11M(2.52M)(498K)(30.43M)(11.69M)
Other Working Capital(14.01M)6.92M(14.48M)(22.09M)15.76M
Other Non-Cash Items25.99M18.98M6.42M7.67M13.56M
Operating Cash Flow70.34M82.13M68.23M52.2M114.6M
Capital Expenditures(19.22M)(22.94M)(28.53M)(8.03M)(10.11M)
Acquisitions (Net)(3.91M)(18.46M)(7.54M)(156.14M)(548.6M)
Purchases of Investments(28M)(1.85M)(6.15M)(2.61M)0
Sales of Investments67.61M31.67M491K124K15.1M
Other Investing Activities56K4.47M(23.8M)(25.74M)4.61M
Investing Cash Flow16.54M(7.11M)(65.52M)(192.4M)(539M)
Debt Repayment(58.69M)(828K)79.17M152.71M604.81M
Common Stock Issued40.13M0000
Common Stock Repurchased(5.74M)(9.25M)(10.19M)(937K)(15.43M)
Dividends Paid(31.09M)(14.03M)(62.07M)(4.04M)(7.89M)
Other Financing Activities(1.42M)4.02M(5.01M)(12.59M)(12.15M)
Financing Cash Flow(47.75M)(20.09M)3.42M135.15M569.35M
Effect of Forex Changes00000
Net Change in Cash39.13M54.93M6.13M(5.05M)144.94M
Free Cash Flow51.11M59.19M39.7M44.17M104.49M

Astrana Health, Inc.

NASDAQ:ASTH

Intrinsic Alpha fair value

Locked

Current Price

$29.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.